| Andrea Dunklow, | |
|
1105 6th St, Traverse City, MI 49684-2349 | |
| (231) 947-0673 | |
| (801) 740-2847 |
| Full Name | Andrea Dunklow |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 1105 6th St, Traverse City, Michigan |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053713479 | NPI | - | NPPES |
| 4704252790 | Other | MI | LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 4704252790 (Michigan) | Primary |
| Entity Name | Munson Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083761860 PECOS PAC ID: 3072426287 Enrollment ID: O20040108000904 |
News Archive
Patients with advanced bladder cancers that are surgically removed might need additional therapy to prevent recurrence in certain situations, a new UT Southwestern Medical Center study suggests.
Three papers published this month in the open access general medical journal PLoS Medicine investigate how tumors respond to a an important class of drugs used in cancer chemotherapy, known as epidermal growth factor receptor (EGFR) inhibitors.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
NovaBay Pharmaceuticals, Inc. today announced that its lead product candidate was safe and efficacious against the highly contagious skin infection impetigo in a Phase 2a proof-of-concept clinical trial. This dose-ranging study showed that the drug cleared impetigo infections, including those in the trial caused by a drug-resistant strain of bacteria called methicillin-resistant Staphylococcus aureus or MRSA. Impetigo afflicts approximately 1 million people, primarily infants and children, in the United States annually.
In a commentary published in the December 2, 2009 issue of the Journal of the American Medical Association, Charles H. Hennekens, M.D., the first Sir Richard Doll Research Professor in the Charles E. Schmidt College of Biomedical Science at Florida Atlantic University, said, "To detect the most likely small to moderate benefits or harm of drugs requires randomized trials of sufficient size and duration. Overreliance on small trials, meta-analyses or subgroup analyses can lead to misleading conclusions."
› Verified 1 days ago
| Entity Name | Northwestern Michigan Emergency Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073597944 PECOS PAC ID: 7214933928 Enrollment ID: O20061019000359 |
News Archive
Patients with advanced bladder cancers that are surgically removed might need additional therapy to prevent recurrence in certain situations, a new UT Southwestern Medical Center study suggests.
Three papers published this month in the open access general medical journal PLoS Medicine investigate how tumors respond to a an important class of drugs used in cancer chemotherapy, known as epidermal growth factor receptor (EGFR) inhibitors.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
NovaBay Pharmaceuticals, Inc. today announced that its lead product candidate was safe and efficacious against the highly contagious skin infection impetigo in a Phase 2a proof-of-concept clinical trial. This dose-ranging study showed that the drug cleared impetigo infections, including those in the trial caused by a drug-resistant strain of bacteria called methicillin-resistant Staphylococcus aureus or MRSA. Impetigo afflicts approximately 1 million people, primarily infants and children, in the United States annually.
In a commentary published in the December 2, 2009 issue of the Journal of the American Medical Association, Charles H. Hennekens, M.D., the first Sir Richard Doll Research Professor in the Charles E. Schmidt College of Biomedical Science at Florida Atlantic University, said, "To detect the most likely small to moderate benefits or harm of drugs requires randomized trials of sufficient size and duration. Overreliance on small trials, meta-analyses or subgroup analyses can lead to misleading conclusions."
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Andrea Dunklow, 4624 N Spider Lake Rd, Traverse City, MI 49696-8440 Ph: (231) 947-0673 | Andrea Dunklow, 1105 6th St, Traverse City, MI 49684-2349 Ph: (231) 947-0673 |
News Archive
Patients with advanced bladder cancers that are surgically removed might need additional therapy to prevent recurrence in certain situations, a new UT Southwestern Medical Center study suggests.
Three papers published this month in the open access general medical journal PLoS Medicine investigate how tumors respond to a an important class of drugs used in cancer chemotherapy, known as epidermal growth factor receptor (EGFR) inhibitors.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
NovaBay Pharmaceuticals, Inc. today announced that its lead product candidate was safe and efficacious against the highly contagious skin infection impetigo in a Phase 2a proof-of-concept clinical trial. This dose-ranging study showed that the drug cleared impetigo infections, including those in the trial caused by a drug-resistant strain of bacteria called methicillin-resistant Staphylococcus aureus or MRSA. Impetigo afflicts approximately 1 million people, primarily infants and children, in the United States annually.
In a commentary published in the December 2, 2009 issue of the Journal of the American Medical Association, Charles H. Hennekens, M.D., the first Sir Richard Doll Research Professor in the Charles E. Schmidt College of Biomedical Science at Florida Atlantic University, said, "To detect the most likely small to moderate benefits or harm of drugs requires randomized trials of sufficient size and duration. Overreliance on small trials, meta-analyses or subgroup analyses can lead to misleading conclusions."
› Verified 1 days ago
Harriet Sue Barner, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1000 Pavillions Cir, Traverse City, MI 49684 Phone: 231-932-3000 Fax: 231-932-3801 | |
Ms. Christine Marie Sykes, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 10767 E Traverse Hwy, Traverse City, MI 49684 Phone: 231-947-1112 | |
Kellie Ann Herringa, NP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1000 Pavillions Cir, Traverse City, MI 49684 Phone: 231-932-3000 Fax: 231-932-3801 | |
Ms. Karri G Hagan, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 815 Business Park Dr Ste A, Traverse City, MI 49686 Phone: 231-421-6921 Fax: 231-421-7852 | |
Matthew Nathan Smith, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 777 E River Rd, Traverse City, MI 49696 Phone: 734-730-2793 | |
Carol Jean Sodman, RNC WHNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1135 E 8th St, Traverse City, MI 49686 Phone: 231-929-1844 Fax: 231-949-2084 | |
Laura A. Schmidt, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 921 W Front St, Traverse City, MI 49684 Phone: 231-995-3657 |